SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+7.71%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.21B
AUM Growth
+$1.21B
(-24%)
Cap. Flow
-$442M
Cap. Flow
% of AUM
-36.55%
Top 10 Holdings %
Top 10 Hldgs %
62.3%
Holding
87
New
11
Increased
22
Reduced
15
Closed
26
Top Buys
| 1 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$47.9M |
| 2 |
Incyte
INCY
|
$47.2M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$21M |
| 4 |
IDEAYA Biosciences
IDYA
|
$18.9M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$14.5M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$100M |
| 2 |
Stryker
SYK
|
$65.7M |
| 3 |
Align Technology
ALGN
|
$52.8M |
| 4 |
Intuitive Surgical
ISRG
|
$38.8M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$35.9M |
Sector Composition
| 1 | Healthcare | 99.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Avidity Biosciences
RNA
$6.12B
| $1.4M | 0.11% |
30,472
+9,047
| +42% | +$416K |
|
52
Vir Biotechnology
VIR
$765M
| $968K | 0.08% |
+129,246
| New | +$968K |
|
53
Astria Therapeutics
ATXS
$394M
| $943K | 0.07% |
85,640
+24,948
| +41% | +$275K |
|
|
IMTXW
54
DELISTED
Immatics N.V. Warrants
IMTXW
| $852K | 0.07% |
366,568
+17,837
| +5% | +$41.5K |
|
|
IMA
55
ImageneBio, Inc. Common Stock
IMA
$153M
| $662K | 0.05% |
382,616
| – | – |
|
56
Replimune Group
REPL
$460M
| $528K | 0.04% |
+48,138
| New | +$528K |
|
57
Pulmonx
LUNG
$67.6M
| $517K | 0.04% |
62,313
+2,067
| +3% | +$17.1K |
|
|
AXNX
58
DELISTED
Axonics, Inc. Common Stock
AXNX
| – | – |
-150,490
| Closed | -$10.1M |
|
59
Kyverna Therapeutics
KYTX
$161M
| – | – |
-47,850
| Closed | -$359K |
|
60
Zimmer Biomet
ZBH
$20.8B
| – | – |
-10,630
| Closed | -$1.15M |
|
61
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
0
| – | – |
|
62
Waters Corp
WAT
$17.3B
| – | – |
-21,804
| Closed | -$6.33M |
|
63
Teleflex
TFX
$5.57B
| – | – |
-13,649
| Closed | -$2.87M |
|
|
64
Stryker
SYK
$149B
| – | – |
-193,084
| Closed | -$65.7M |
|
65
DexCom
DXCM
$30.9B
| – | – |
-61,494
| Closed | -$6.97M |
|
66
Celldex Therapeutics
CLDX
$1.57B
| – | – |
-547,707
| Closed | -$20.3M |
|
67
Baxter International
BAX
$12.1B
| – | – |
-117,769
| Closed | -$3.94M |
|
68
Avantor
AVTR
$8.74B
| – | – |
-141,045
| Closed | -$2.99M |
|
|
69
Ascendis Pharma
ASND
$12.1B
| – | – |
-734,284
| Closed | -$100M |
|
70
Amylyx Pharmaceuticals
AMLX
$877M
| – | – |
-299,691
| Closed | -$569K |
|
|
71
Alnylam Pharmaceuticals
ALNY
$58.6B
| – | – |
-147,929
| Closed | -$35.9M |
|
|
72
Align Technology
ALGN
$9.59B
| – | – |
-218,524
| Closed | -$52.8M |
|
73
Abbott
ABT
$230B
| – | – |
0
| – | – |
|
74
Sarepta Therapeutics
SRPT
$1.98B
| – | – |
-195,852
| Closed | -$30.9M |
|
75
Roivant Sciences
ROIV
$8.6B
| – | – |
-1,868,412
| Closed | -$19.7M |
|